Deerfield Management Company L.P. Series C Invests $279,000 in Addus HomeCare Co. (NASDAQ:ADUS)

Deerfield Management Company L.P. Series C purchased a new position in Addus HomeCare Co. (NASDAQ:ADUS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,407 shares of the company’s stock, valued at approximately $279,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. raised its stake in shares of Addus HomeCare by 64.2% in the second quarter. UMB Bank n.a. now owns 225 shares of the company’s stock valued at $26,000 after buying an additional 88 shares during the period. Quest Partners LLC bought a new position in Addus HomeCare during the second quarter worth about $31,000. Innealta Capital LLC purchased a new position in shares of Addus HomeCare in the second quarter worth about $44,000. EntryPoint Capital LLC bought a new stake in shares of Addus HomeCare in the first quarter valued at approximately $44,000. Finally, Sandia Investment Management LP purchased a new stake in shares of Addus HomeCare during the 2nd quarter valued at approximately $58,000. 95.35% of the stock is owned by institutional investors.

Addus HomeCare Trading Down 0.7 %

ADUS stock opened at $130.95 on Friday. The company’s 50 day moving average is $128.25 and its 200 day moving average is $115.31. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 32.49, a price-to-earnings-growth ratio of 2.40 and a beta of 1.04. Addus HomeCare Co. has a 1-year low of $78.35 and a 1-year high of $136.12.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings results on Monday, August 5th. The company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The firm had revenue of $286.90 million for the quarter, compared to analyst estimates of $284.90 million. During the same quarter in the prior year, the firm earned $0.94 EPS. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Addus HomeCare Co. will post 4.58 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Esteban Lopez sold 500 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $130.03, for a total transaction of $65,015.00. Following the transaction, the director now directly owns 3,866 shares of the company’s stock, valued at approximately $502,695.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Esteban Lopez sold 500 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $130.03, for a total value of $65,015.00. Following the completion of the sale, the director now owns 3,866 shares of the company’s stock, valued at approximately $502,695.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael D. Wattenbarger sold 21,917 shares of Addus HomeCare stock in a transaction on Monday, August 26th. The stock was sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the transaction, the executive vice president now owns 7,215 shares in the company, valued at approximately $961,687.35. The disclosure for this sale can be found here. Insiders sold a total of 22,917 shares of company stock valued at $3,050,082 over the last 90 days. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Stephens reiterated an “overweight” rating and issued a $138.00 price objective on shares of Addus HomeCare in a research note on Tuesday, August 6th. Macquarie started coverage on Addus HomeCare in a research note on Friday, June 28th. They set an “outperform” rating and a $136.00 price objective on the stock. Oppenheimer raised their target price on Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. TD Cowen upped their price target on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, StockNews.com downgraded shares of Addus HomeCare from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 7th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Addus HomeCare has an average rating of “Moderate Buy” and an average price target of $128.29.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.